STAT3 and ovarian cancer: Early studies reported that inhibition of the constitutively activated Stat3 by using the Janus Kinase-selective inhibitor (AG490) suppresses ovarian cancer growth12, and disruption of constitutively activated STAT3 overcomes ovarian cancer cisplatin resistance13.